• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Stacy Lawrence

Articles by Stacy Lawrence

Smith & Nephew nabs Osiris in $660M deal; regen med firm adds to wound healing business

March 13, 2019
By Stacy Lawrence
Osiris Therapeutics Inc. is slated to be acquired by orthopedics player Smith & Nephew plc for about $660 million in cash. The deal is focused on skin substitutes – particularly allografts made of donor tissue that the London-based company expects will help to ramp up its wound management business.
Read More

FDA grants the first breakthrough device designation for AI in cancer Dx

March 11, 2019
By Stacy Lawrence
New York-based startup Paige.AI has gained the first disclosed breakthrough device designation from the U.S. FDA for the application of artificial intelligence (AI) in cancer diagnosis. Pathology is an obvious early place for AI in health care; it's imaging-heavy, and a segment where AI is already being integrated. In addition, there's a high degree of variability between pathologists in their assessments, while digital pathology slides are becoming more commonplace, and patient outcomes could be improved by more accurate, consistent pathology reports.
Read More

Shockwave $97M IPO prices high, trades up 80 percent to back novel atherosclerosis tech

March 8, 2019
By Stacy Lawrence
Shockwave Medical Inc. is aiming to establish a new standard of care for the minimally invasive treatment of atherosclerotic cardiovascular disease. Its intravascular lithotripsy (IVL) system uses sonic pressure waves to remove calcified plaque that narrows or blocks the blood vessels connected to the heart.
Read More

Novel nanowire sensor could enable remote imaging

March 8, 2019
By Stacy Lawrence

FDA gives nod to real-time monitor to detect endovascular procedure bleeds from Saranas

March 6, 2019
By Stacy Lawrence

NIH study finds epigenetic 'clocks' can aid prediction of breast cancer risk

March 4, 2019
By Stacy Lawrence

Rani says robotic, auto-injection pill shows safety in first human trial

March 1, 2019
By Stacy Lawrence
Startup Rani Therapeutics LLC has gotten positive safety results in a first-in-human trial of its pill that's designed to enable painless injections of biologic drugs into the small intestine. Later this year, the San Jose, Calif.-based company plans to start a clinical trial with the robotic pill that includes a drug-filled resorbable needle – the initial safety test was without any drug.
Read More

Rani says robotic, auto-injection pill shows safety in first trial

March 1, 2019
By Stacy Lawrence
Startup Rani Therapeutics LLC has gotten positive safety results in a first-in-human trial of its pill that's designed to enable painless injections of biologic drugs into the small intestine. Later this year, the San Jose, Calif.-based company plans to start a clinical trial with the robotic pill that includes a drug-filled resorbable needle – the initial safety test was without any drug.
Read More

FDA gives breakthrough designation to first potential IVD test for Alzheimer's to Fujirebio

Feb. 28, 2019
By Stacy Lawrence

NIH study finds epigenetic 'clocks' can aid prediction of breast cancer risk

Feb. 28, 2019
By Stacy Lawrence
Genetics can only tell us so much when it comes to understanding cancer. It turns out that interrogating the myriad processes involved in the translation of DNA into actual bodily processes, as well as alterations over time, are crucial. To that end, researchers at the NIH are pursuing a more refined understanding of epigenetics, which is defined by how biochemical processes work to modify gene expression.
Read More
Previous 1 2 … 26 27 28 29 30 31 32 33 34 … 80 81 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe